Profile data is unavailable for this security.
About the company
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
- Revenue in USD (TTM)3.84bn
- Net income in USD330.79m
- Incorporated2005
- Employees2.80k
- LocationJazz Pharmaceuticals PLCFifth FlWaterloo Exchange, Waterloo RoadDUBLIN 4IrelandIRL
- Phone+353 16347800
- Fax+353 16347850
- Websitehttps://www.jazzpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | JAZZ:NSQ since announced | Transaction value |
|---|---|---|
| Redx Pharma PLC-KRAS Inhibitor Program | -10.15% | -- |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon & Co | 6.35bn | 1.05bn | 5.37bn | 10.00k | 5.12 | 111.29 | 4.16 | 0.846 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 5.55bn | 423.00 | -- | -- | -- | 1,478.34 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 5.64bn | 373.00 | 18.32 | 31.69 | 14.06 | 6.53 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.85bn | 927.00 | -- | 19.70 | -- | 7.53 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 6.20bn | 28.00 | -- | 6.64 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Exelixis Inc | 1.85bn | 205.05m | 6.33bn | 1.31k | 33.62 | 3.01 | 27.50 | 3.43 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.38bn | 645.00 | -- | 20.53 | -- | 22.61 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.56bn | 411.00 | -- | 3.80 | -- | 1,437.40 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.59bn | 2.80k | 21.56 | 1.78 | 6.73 | 1.71 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Intra-Cellular Therapies Inc | 513.93m | -110.87m | 7.17bn | 610.00 | -- | 11.04 | -- | 13.94 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.41bn | 355.00 | -- | 13.10 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 342.80m | -465.95m | 7.54bn | 1.80k | -- | 6.47 | -- | 21.98 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Vaxcyte Inc | 0.00 | -436.82m | 7.72bn | 254.00 | -- | 3.89 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Bellring Brands Inc | 1.84bn | 191.50m | 7.88bn | 420.00 | 42.01 | -- | 33.32 | 4.27 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
Data as of Jun 07 2024. Currency figures normalised to Jazz Pharmaceuticals PLC's reporting currency: US Dollar USD
38.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.30m | 9.99% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.61m | 8.90% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.46m | 3.91% |
| LSV Asset Managementas of 31 Mar 2024 | 2.38m | 3.78% |
| Polaris Capital Management LLCas of 31 Mar 2024 | 1.43m | 2.27% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.43m | 2.27% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 1.34m | 2.13% |
| Pacer Advisors, Inc.as of 31 Mar 2024 | 1.29m | 2.05% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.17m | 1.85% |
| Camber Capital Management LPas of 31 Mar 2024 | 1.15m | 1.82% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
